These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37773814)

  • 21. Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet.
    Fiore CE; Pennisi P; Ferro G; Ximenes B; Privitelli L; Mangiafico RA; Santoro F; Parisi N; Lombardo T
    Horm Metab Res; 2006 Jun; 38(6):417-22. PubMed ID: 16823725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations of Bone Mineral Density with RANKL and Osteoprotegerin in Arab Postmenopausal Women: A Cross-Sectional Study.
    Amer OE; Wani K; Ansari MGA; Alnaami AM; Aljohani N; Abdi S; Hussain SD; Al-Daghri NM; Alokail MS
    Medicina (Kaunas); 2022 Jul; 58(8):. PubMed ID: 35893092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
    Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.
    Muskiet MHA; Bunck MC; Heine RJ; Cornér A; Yki-Järvinen H; Eliasson B; Joles JA; Diamant M; Tonneijck L; van Raalte DH
    Diabetes Res Clin Pract; 2019 Jul; 153():14-22. PubMed ID: 31078666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
    Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.
    Rogers A; Saleh G; Hannon RA; Greenfield D; Eastell R
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4470-5. PubMed ID: 12364420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Zuoguiwan on osteoporosis in ovariectomized rats through RANKL/OPG pathway mediated by β2AR.
    Liu F; Tan F; Tong W; Fan Q; Ye S; Lu S; Teng Z; Han M; Zhang M; Chai Y
    Biomed Pharmacother; 2018 Jul; 103():1052-1060. PubMed ID: 29710663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia.
    Honsawek S; Chaiwatanarat T; Vejchapipat P; Chongsrisawat V; Thawornsuk N; Poovorawan Y
    Pediatr Surg Int; 2009 Mar; 25(3):261-7. PubMed ID: 19184056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.
    Zhao HY; Liu JM; Ning G; Zhao YJ; Chen Y; Sun LH; Zhang LZ; Xu MY; Chen JL
    Osteoporos Int; 2008 Feb; 19(2):221-6. PubMed ID: 17703270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M; Fathy SA; Mehany NL; Hindy OW
    Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.
    Zheng H; Wang C; He JW; Fu WZ; Zhang ZL
    Pharmacogenet Genomics; 2016 Jan; 26(1):12-9. PubMed ID: 26426211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physical training increases osteoprotegerin in postmenopausal women.
    Bergström I; Parini P; Gustafsson SA; Andersson G; Brinck J
    J Bone Miner Metab; 2012 Mar; 30(2):202-7. PubMed ID: 21823052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women.
    Mainini G; Incoronato M; Urso L; Scaffa C
    Clin Exp Obstet Gynecol; 2011; 38(4):355-9. PubMed ID: 22268274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
    Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E
    Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role?
    Gaudio A; Lasco A; Morabito N; Atteritano M; Vergara C; Catalano A; Fries W; Trifiletti A; Frisina N
    J Endocrinol Invest; 2005 Sep; 28(8):677-82. PubMed ID: 16277162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes.
    Li R; Xu W; Luo S; Xu H; Tong G; Zeng L; Zhu D; Weng J
    Acta Diabetol; 2015 Dec; 52(6):1083-91. PubMed ID: 26249206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA.
    Arslan MS; Sahin M; Karakose M; Tutal E; Topaloglu O; Ucan B; Demirci T; Caliskan M; Ozdemir S; Ozbek M; Cakal E
    Endocr Pract; 2017 Mar; 23(3):266-370. PubMed ID: 27849387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
    Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salidroside Improves Bone Histomorphology and Prevents Bone Loss in Ovariectomized Diabetic Rats by Upregulating the OPG/RANKL Ratio.
    Zheng H; Qi S; Chen C
    Molecules; 2018 Sep; 23(9):. PubMed ID: 30235836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.